conference reports
Hospitalistion after renal ablation unecessary
Thursday, 8 April 2010- Ablation of renal masses can be performed routinely as outpatient procedures and usually do not require hospital admission for post-procedure observation, researchers reported here at the Society of...
Edited by: ES
Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma
Monday, 5 April 2010- Sunitinib is a front-line standard of care in patients with metastatic renal cell carcinoma (mRCC). Patients who progress during treatment with sunitinib typically are treated with multiple sequential...
Edited by: JV
Cytoreductive nephrectomy in mRCC patients treated with VEGF-targeted therapy
Tuesday, 30 March 2010- VEGF-targeted therapy is the standard of care in patients with metastatic renal cell carcinoma (mRCC). Cytoreductive nephrectomy (CN) is a standard of care as defined in the cytokine era, although not...
Edited by: JV
Sequential use of temsirolimus in mRCC patients after failed TKI treatment
Thursday, 25 March 2010- Agents targeting the mTOR pathway may provide clinical benefit in pre-treated metastatic renal cell carcinoma (mRCC) patients, but data from prospective randomised trials on the sequential use of...
Edited by: JV
Phase 3 AVOREN trial: OS improvement in mRCC patients given bevacizumab and interferon
Wednesday, 17 March 2010- Bevacizumab (BEV) plus interferon (IFN) is an active first-line treatment option for patients (pts) with metastatic renal cell carcinoma (mRCC), demonstrated to significantly improve median...
Edited by: JV
Early response to preoperative targeted therapy for mRCC may reveal efficacy
Friday, 12 March 2010- Early response to preoperative targeted therapy for metastatic renal cell carcinoma may indicate efficacy, while treatment-induced hypertension may be another marker after surgery, according to researchers...
Edited by: JV
7th ESOU Meeting: key messages, renal cancer session
Tuesday, 19 January 2010- Key treatment issues, complications and emerging diagnostic and surgical techniques in renal cancer were discussed in the recent 7th Meeting of the EAU Section of Oncological Urology (ESOU)...
By Joel Vega
Compariing pazopanib’s efficacy in cytokine pretreated patients with advanced RCC
Wednesday, 30 December 2009- Pazopanib, an oral multikinase angiogenesis inhibitor, has shown clinical efficacy in patients with advanced RCC. In a study (VEG105192) by C. Sternberg and colleagues, the efficacy and safety of...
Edited by: Joel Vega
More medical options for mRCC but progress needed to reduce toxicities, identify biomarkers
Thursday, 10 December 2009- More medical treatment options are available to patients with metastatic renal cell carcinoma (mRCC), but more progress is needed particularly in terms of boosting the safety or reducing the...
By Joel Vega
Bladder cancer and RCC: from diagnosis to follow-up
Wednesday, 2 December 2009 - Various aspects related to the diagnosis, prognosis and treatment of bladder cancer were dealt with in the framework of several sections of the 2nd Multidisciplinary Meeting on Urological Cancers held...
By Evgenia Starkova
